Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Oncology NewsFutibatinib Approved for Certain Patients with Advanced Intrahepatic Cholangiocarcinoma

The FOENIX*-CCA2 trial, a global phase 2, open-label trial examining 103 patients with unresectable, locally progressed, or metastatic iCCA harboring FGFR2 gene rearrangements including fusions, was the basis for the approval of futibatinib (Lytgobi, Taiho Oncology). Patients in this trial received 20 mg of futibatinib orally once daily until disease progression or intolerable toxicity; the primary end goal was achieved with a 42% objective response rate as determined by an impartial central evaluation. With 72% of responses lasting at least six months, the median response time was 9.7 months.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form